A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 262 participants.

Also called NCT04358432

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 262 participants (enrolled count) (from the registry)
Sponsor
  • Akeso Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04358432
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04358432. Randomized; triple masking; primary purpose treatment. Start 2020-05-13 (actual); primary completion 2021-02-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
Condition
Hypercholesterolemia
Intervention (Drug)
AK102
Intervention (Drug)
Placebos
Intervention (Drug)
Statins and/or Ezetimibe
Lead sponsor
Akeso (class: industry)
Collaborator
AD Pharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04358432
Content hash
3c48bffdf8135c7fd6fb9fbb310494792855b409e9788df57a26a30cc712b228